Acceleron Pharma

Investors & Media

Press Releases

Date Title and Summary
Toggle Summary Acceleron to Participate in Two Upcoming Healthcare Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 26, 2020-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics intended to treat serious and rare diseases, today announced that senior management will participate in
Toggle Summary Acceleron to Webcast Fourth Quarter and Full Year 2019 Operating and Financial Results on February 27, 2020
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 18, 2020-- Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, February 27, 2020 at 5:00 p.m. EST to discuss its fourth quarter and full year 2019 operating and financial results.
Toggle Summary Acceleron Announces Sotatercept Achieved Primary and Secondary Endpoints in the PULSAR Phase 2 Placebo-Controlled Trial in Patients with Pulmonary Arterial Hypertension
- The PULSAR trial achieved its primary endpoint: a statistically significant reduction in pulmonary vascular resistance - - The trial also achieved statistically significant improvements in the key secondary endpoint of six-minute walk distance (6MWD) and other secondary endpoints, including
Toggle Summary Acceleron Announces Change to Executive Management Team
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 23, 2020-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that John Quisel , J.D., Ph.D, Executive Vice
Toggle Summary New England Journal of Medicine Publishes Results of Pivotal Phase 3 Reblozyl® (luspatercept-aamt) MEDALIST Trial
Data from MEDALIST showed significant clinical benefit of Reblozyl in treating anemia in adults with myelodysplastic syndromes PRINCETON, N.J. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 9, 2020-- Bristol-Myers Squibb Company (NYSE:BMY) and Acceleron Pharma Inc.
Toggle Summary Acceleron to Participate in the 38th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 6, 2020-- Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that senior management will participate at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California . On Monday, January 13, 2020 , Habib Dable , Acceleron’s President and
Toggle Summary Acceleron and Fulcrum Therapeutics Announce Pulmonary Research and Discovery Collaboration Agreement
Fulcrum to receive $10 million upfront payment and be eligible for future milestone payments CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 30, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat
Toggle Summary Reblozyl® (luspatercept-aamt) Studies Evaluating Treatment of Anemia in Rare Blood Diseases Presented at American Society of Hematology (ASH) Annual Meeting
Initial results from phase 2 study evaluating an investigational use of luspatercept-aamt in myelofibrosis-associated anemia showed promising clinical activity – companies plan to initiate pivotal, phase 3 study called INDEPENDENCE in 2020 Longer-term follow-up from pivotal phase 3 studies of
Toggle Summary Acceleron Appoints Jay T. Backstrom, M.D., M.P.H., to Newly Created Role as Head of Research and Development
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 9, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Jay T.
Toggle Summary Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® (luspatercept-aamt)
PRINCETON, N.J. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 6, 2019-- Bristol-Myers Squibb Company (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that following the late-cycle review meeting on December 4, 2019 , they were notified by the U.S.